These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24926065)

  • 1. Paving the road to MRD-guided treatment in CLL.
    Böttcher S
    Blood; 2014 Jun; 123(24):3683-4. PubMed ID: 24926065
    [No Abstract]   [Full Text] [Related]  

  • 2. Coexistence of myelodysplastic syndrome and untreated chronic lymphocytic leukemia with development of acute myeloid leukemia immediately after treatment of chronic lymphocytic leukemia.
    Bracey AW; Maddox AM; Immken L; Hsu SM; Marks ME
    Am J Hematol; 1989 Mar; 30(3):174-80. PubMed ID: 2916561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of chronic lymphocytic leukemia in relation to clinico- morphological characteristics of the disease].
    Tumakov VA; Abdulkadyrov KM; Rugal' VI; Karpenkov MV; Ved' VV; Brodovskiĭ AF
    Klin Med (Mosk); 1991 Jan; 69(1):94-7. PubMed ID: 2023411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements.
    Vuillier F; Claisse JF; Vandenvelde C; Travade P; Magnac C; Chevret S; Desablens B; Binet JL; Dighiero G
    Leuk Lymphoma; 1992 Jun; 7(3):195-204. PubMed ID: 1282428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
    Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
    J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic lymphocytic leukemia associated with bone marrow fibrosis: possible role of interleukin 1 alpha in the pathogenesis.
    Kimura A; Hyodo H; Nakata Y; Kuramoto A
    Am J Hematol; 1993 May; 43(1):47-50. PubMed ID: 8317461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy-related acute myeloblastic leukemia after splenectomy in a patient with composite lymphoma developing after treatment of chronic lymphocytic leukemia.
    Valković T; Seili-Bekafigo I; Bašić-Kinda S; Labar B; Duletić-Načinović A; Pećanić S; Jonjić N
    Ann Hematol; 2014 Jun; 93(6):1057-9. PubMed ID: 24101115
    [No Abstract]   [Full Text] [Related]  

  • 8. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevance of Minimal Residual Disease in the Era of Targeted Agents.
    Heltai S; Ghia P; Scarfò L
    Cancer J; 2019; 25(6):410-417. PubMed ID: 31764122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-CLL in PLL transformation associated with hypercalcemia.
    Lerner D; Esteves C; De Oliveira MS
    Leuk Lymphoma; 1994 Jan; 12(3-4):321-5. PubMed ID: 8167564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit with MRD-guided treatment in CLL.
    Romero D
    Nat Rev Clin Oncol; 2024 Feb; 21(2):84. PubMed ID: 38167875
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
    Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
    J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential development of monoclonal B cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia.
    Suzuki Y; Koya J; Ebisawa K; Abe H; Shinozaki-Ushiku A; Nakamura F; Kurokawa M
    Ann Hematol; 2018 May; 97(5):917-919. PubMed ID: 29417202
    [No Abstract]   [Full Text] [Related]  

  • 17. Watch and Wait in Lebanese Chronic Lymphocytic Leukemia Patients: How Relevant is it?
    Lutfallah AA; Kourie HR; Eid R; Farhat F; Ghosn M; Kattan J
    Asian Pac J Cancer Prev; 2016; 17(1):215-7. PubMed ID: 26838212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexistence of Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia.
    Milosevic I
    Turk J Haematol; 2016 Dec; 33(4):353-354. PubMed ID: 27751969
    [No Abstract]   [Full Text] [Related]  

  • 19. The influence of chemotherapy on bone marrow in patients with chronic lymphocytic leukaemia.
    Lemancewicz D; Dziecioł J; Kłoczko J; Piszcz J
    Folia Morphol (Warsz); 2004 Nov; 63(4):485-9. PubMed ID: 15712148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idelalisib Bolsters CLL Regimen.
    Leslie M
    Cancer Discov; 2016 Mar; 6(3):OF2. PubMed ID: 26772993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.